奥沙利铂联合5-FU／CF方案治疗肝癌复发转移的临床观察

Clinical study of the combination of oxaliplatin, 5-fluorouracil（5-FU） and calciumfolinate （CF） in the treatment of patients with advanced primary hepatocellular carcinoma

目的 探讨奥沙利铂联合5-Fu（5-氟脲嘧啶）／CF（醛氢叶酸钙）方案治疗肝癌复发转移的疗效及安全性。方法26例为全身多发转移的原发性肝癌病人，给予奥沙利铂130mg／m^2，iv，d1；CF100mg，iv，5-FU450mg／m^2，iv，d1-5。4wk重复，2周期后复查，进展者停止化疗，余继续化疗4个周期。结果26例病人都可以作出评价：其中CR1例、PR8例、SD8例和PD9例，总有效率（CR＋PR）34．62％：AFP情况与疗效无关（P〉0．05）。随访截止，17例病人死亡，中位生存时间（MST）8．5mo，1a生存率76.7％。有效病人的MST为13．6mo，TTP为3．8mo，无效的MST为6．5mo。未发生Ⅲ-Ⅳ度毒性反应。结论奥沙利铂联合5-FU／CF方案治疗肝癌多发转移安全有效.

objective To evaluate the efficacy and toxicity of the combination of oxaliplatin, 5-fluorouracil （5-FU） and calcium folinate（CF） in the treatment of patients with advanced primary hepatocellular carcinoma. Methods Total of 26 patients with advanced primary hepatocellular carcinoma received oxaliplatin 130mg/m^2 dl iv drip, and 5-FU 450 mg/m^2 d1-5 iv drip, CF100 mg d1-5 iv drip. 4 weeks is a course of treatment. Results All 26 patients were evaluated for therapeutic effect. The overall response rate （CR＋PR） was 34.62% （9/26）. CR was 1 case, PR was 8, SD was 8, and PD was 9. The situation of AFP was not related with the efficacy. When the follow-up ended in Nov. 2007, 17 patients were dead. MST and 1 year survival rate of these dead patients was 8.5 months and 76.7%, respectively. MST and TIP of responsive patients were 13.6 months and 3.8 months. MST of invalid patients was 6.5 months. Ⅲ-Ⅳ degree toxicity was not observed. Conclusions Combination of oxaliplatin, CF and 5-FU is an effective and safe regimen in the treatment of patients with advanced primary hepatocellular carcinoma.